Broad 66 gene panel for diagnosing and prognosticating lymphoid disorders.
This panel offers comprehensive testing for genomic variants that can provide diagnostic and prognostic information for patients with lymphoid disorders including chronic lymphocytic leukaemia, mantle cell lymphoma, hairy cell leukaemia, lymphoplasmacytic lymphoma and follicular lymphoma. It is based on international guidelines and best practices. If required, customisation to suit individual patient needs can be offered.
Lymphoid 66 gene panel
For diagnostic/prognostic work up of lymphoid malignancies
ARID1A, ASXL1, ATM, B2M, BCL2, BIRC3, BRAF, BTK, CARD11, CCND1, CD79B, CREBBP, CRLF2, CXCR4, DNMT3A, EP300, ETV6, EZH2, FBXW7, FLT3, FOXO1, GNA13, ID3, IDH1, IDH2, IKZF1, IL7R, JAK1, JAK2, JAK3, KLF2, KMT2D, KRAS, MAP2K1, MEF2B, MYC, MYD88, NF1, NFKBIE, NOTCH1, NOTCH2, NRAS, PAX5, PHF6, PIM1, PLCG2, POT1, PRDM1, PTEN, PTPN11, RHOA, SETD2, SF3B1, SH2B3, SOCS1, STAT3, STAT5B, STAT6, TCF3, TET2, TNFAIP3, TNFRSF14, TP53, U2AF1, WT1 and XPO1
Next generation sequencing
3 – 4 weeks
If not MBS eligible please contact 1800 822 999 for details
Haematology Cancer Genetics request form preferred, standard pathology request form accepted
Blood 4mL EDTA tube or Bone Marrow 4mL EDTA tube or FFPE
Blood or bone marrow aspirate or lymph node. Bone marrow trephines/blocks will not be accepted for testing due to the DNA damage caused by the decalcification process.
Specialist/consultant physician request only. These panels do not cover fusion genes or CNV (Copy Number Variations).
